Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS
Home/The Filing Wire/Zura Bio Limited/ 10-Q

Quarterly Report · 10-Q

Zura Bio Limited

ZURANASDAQEQUITYCurrent

Quarterly Report

Filed Nov 13, 2025Accepted Nov 13, 2025, 6:32 AM ESTCIK 1855644Accession 0001104659-25-110793
View company →Permanent SEC source ↗
Share

Company context

Zura is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases with unmet need. Zura’s pipeline includes product candidates designed to target key mechanisms of immune system imbalance, with the goal of improving efficacy, safety, and dosing convenience for patients. Zura’s lead product candidate, tibulizumab (ZB-106), is being evaluated in two Phase 2 clinical studies in adults: TibuSHIELD, a study in hidradenitis suppurativa (HS), and TibuSURE, a study in systemic sclerosis (SSc). A third Phase 2 clinical study in polymyalgia rheumatica (PMR), NEXUS-PMR, is planned to begin by year-end 2026. Additional product candidates torudokimab (ZB-880) and crebankitug (ZB-168) have completed Phase 1/1b studies and are being evaluated for their potential across a range of autoimmune and inflammatory conditions.

Current securities

ZURANASDAQ · EQUITY · Current
Historical securities (4)
JATTNYSE · EQUITY · Historical · closed Mar 20, 2023JATT.UNNYSE · UNIT · Historical · closed Mar 20, 2023JATT.WSNYSE · WARRANT · Historical · closed Mar 20, 2023ZURAWNASDAQ · WARRANT · Historical · closed Aug 27, 2024

Recent company filings

  1. S-3 filingOct 27, 2026
  2. Results of Operations and Financial Condition · Regulation FD DisclosureOct 27, 2026
  3. 10-Q filingOct 27, 2026
  4. S-8 filingSep 30, 2026
  5. 144 filingAug 18, 2026

Document unavailable

This filing is not currently available in the archive. Read it on SEC EDGAR ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.